Academic Journal
Q1New England Journal of Medicine
About New England Journal of Medicine
New England Journal of Medicine is a scholarly journal published by Massachussetts Medical Society. SCImago 2025 places it in Q1 with an SJR of 18.397 and an H-index of 1275.
Its listed coverage is 1945-2026 and its research categories include Medicine (miscellaneous) (Q1). The 2025 dataset reports 1292 documents and 78334 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Diverse Scientific and Economic Studies, Human auditory perception and evaluation, Medical History and Innovations, Legal case studies and regulations, Legal Cases and Commentary, History of Medical Practice.
Recent Research Articles
Latest publications matched automatically by ISSN.
Tozorakimab to Prevent COPD Exacerbations
Frank C. Sciurba, Henrik Watz, Arnaud Bourdin, Wim Janssens et al.
2026-09-08 · DOI: 10.1056/nejmoa2606998When Fear Became the Barrier to Care — Lessons of a Clinical Rapid Response during Operation Metro Surge
Munira Maalimisaq, Jennifer Needle-Suarez
2026-09-05 · DOI: 10.1056/nejmp2607981The Future of the USPSTF and Evidence-Based Recommendations
Elizabeth Kaplan, Carmel Shachar
2026-09-05 · DOI: 10.1056/nejmp2607441AI-Based Translation of Discharge Instructions — Aligning Policy with Practice
Melanie F. Molina, Mateo C. Rutherford, Elaine C. Khoong
2026-09-05 · DOI: 10.1056/nejmp2603777Adie Tonic Pupil
Aaron Donnelly, Richard Farnan
2026-09-05 · DOI: 10.1056/nejmicm2606883The Long Shadow of Bedlam
Richard Elledge
2026-09-05 · DOI: 10.1056/nejmp2600529Physical Examination for Asymptomatic Adults
Minali Nigam, Allan H. Goroll, Adam S. Cifu
2026-09-03 · DOI: 10.1056/nejmclde2515158Childhood Vaccine Hesitancy
2026-09-03 · DOI: 10.1056/nejmc2608837Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia
Ravi Savarirayan, Julie Hoover-Fong, Melita Irving, Paul Arundel et al.
2026-09-03 · DOI: 10.1056/nejmoa2604565Infigratinib in Achondroplasia — A Potentially Giant Step Forward
Isidro B. Salusky, Harald Jüppner
2026-09-03 · DOI: 10.1056/nejme2609749Scrofuloderma
Ana Rita Ambrosio, Hugo Pego
2026-09-03 · DOI: 10.1056/nejmicm2517515Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia
Amir T. Fathi, Alexander E. Perl, Geoffrey G. Fell, Brian A. Jonas et al.
2026-09-03 · DOI: 10.1056/nejmoa2602804Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer
Kathryn C. Arbour, Salman Punekar, Jia Luo, Melissa Johnson et al.
2026-09-03 · DOI: 10.1056/nejmoa2504059A Zoonotic Orthonairovirus from Febrile Patients in China
Xiao-Ai Zhang, Bo Liu, Si-Qian Wu, Xin Yang et al.
2026-09-03 · DOI: 10.1056/nejmc2602496Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock
Fran Balamuth, Scott L. Weiss, Elliot Long, Graham C. Thompson et al.
2026-09-03 · DOI: 10.1056/nejmoa2601969Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders
Yu-Hang Cheng, Ke Shang, Chuan Qin, Ming-Hao Dong et al.
2026-09-03 · DOI: 10.1056/nejmc2603114Telehealth Access to Mifepristone — Evaluating Reproductive-Coercion Arguments
Elizabeth Tobin-Tyler, Gabriella Chalker
2026-09-03 · DOI: 10.1056/nejmp2608826Pulmonary Nodules
Matthew E.J. Callister, Gerard A. Silvestri
2026-09-03 · DOI: 10.1056/nejmcp2515063Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML
Charles A. Schiffer
2026-09-03 · DOI: 10.1056/nejme2607967Telitacicept for IgA Nephropathy
2026-09-03 · DOI: 10.1056/nejmc2608517Reviews
Community Reviews
Version History
September 7, 2026 at 11:58 pm
September 7, 2026